BamSEC and AlphaSense Join Forces
Learn More

Outlook Therapeutics Inc.

NASDAQ: OTLK    
Share price (12/20/24): $1.44    
Market cap (12/20/24): $34.1 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 10-Q 16 pages Outlook Therapeutics, Inc. 2024 Equity Incentive Plan ​ Stock Option Grant Notice
12/34/56
EX-10.1
from 10-Q 23 pages Outlook Therapeutics, Inc. 2024 Equity Incentive Plan
12/34/56
EX-10.1
from 8-K 3 pages 1. the Defined Term “Agreement” in the Sales Agreement Is Amended to Mean the Sales Agreement as Amended by This Amendment. 2. the Second Paragraph of Section 1 of the Sales Agreement Is Hereby Amended and Restated in Its Entirety as Follows
12/34/56
EX-10.6
from 8-K 5 pages Third Amendment to Convertible Promissory Note
12/34/56
EX-10.5
from 8-K 24 pages Registration Rights Agreement
12/34/56
EX-10.4
from 8-K 44 pages Securities Purchase Agreement
12/34/56
EX-10.3
from 8-K 24 pages Registration Rights Agreement
12/34/56
EX-10.2
from 8-K 9 pages Outlook Therapeutics, Inc. Support Agreement
12/34/56
EX-10.1
from 8-K 46 pages Securities Purchase Agreement
12/34/56
EX-10.30
from 10-K 4 pages Amendment to Convertible Promissory Note
12/34/56
EX-10.26
from 10-K 5 pages Outlook Therapeutics, Inc. ​ Non-Employee Director Compensation Policy ​ as Amended and Restated Effective October 1, 2023
12/34/56
EX-10.1
from 8-K 51 pages Outlook Therapeutics, Inc. Up to $100,000,000 of Common Stock (Par Value $0.01 Per Share) At-The-Market Sales Agreement
12/34/56
EX-10.1
from 10-Q 3 pages Amendment to Convertible Promissory Note
12/34/56
EX-10.38
from 10-K 5 pages Outlook Therapeutics, Inc. ​ Non-Employee Director Compensation Policy ​ as Amended and Restated Effective October 1, 2020
12/34/56
EX-10.2
from 8-K 11 pages Pursuant to Our Recent Discussions, This Letter Agreement (This “Agreement”) Confirms Our Understanding That Outlook Therapeutics, Inc., a Delaware Corporation (Collectively With Its Subsidiaries and Affiliates, the “Company”), Has Engaged M.S. Howells & Co. (The “Placement Agent”) to Act as the Company’s Placement Agent to Introduce It to Certain Investors (The “Investors”) as Prospective Purchasers of the Company’s Shares of Common Stock Par Value $0.01 Per Share (The “Shares”), in Connection With a Registered Direct Financing (The “Transaction”). This Agreement Will Be Effective as of December 22, 2022 (The “Effective Date”) and Will Expire on December 29, 2022
12/34/56
EX-10.1
from 8-K 31 pages Form of Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 9 pages C O N V E R T I B L E P R O M I S S O R Y N O T E
12/34/56
EX-10.1
from 8-K 19 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 14 pages Amended and Restated Executive Employment Agreement
12/34/56
EX-10.1
from 8-K 43 pages Amended and Restated Investor Rights Agreement by and Between Outlook Therapeutics, Inc. and Gms Ventures and Investments Dated April 21, 2022
12/34/56